Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Case Western Reserve University has entered a worldwide licensing agreement with Tracon Pharmaceuticals to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy.
Subscribe to our email newsletter
Under the licensing agreement, Tracon will develop and manage clinical trials of Methoxyamine. Methoxyamine was developed by University Hospitals Case Medical Center researchers.
Research for this new therapeutic came from the National Institutes of Health rapid access to interventional development program, that provides researchers resources and support needed for the development of new therapeutics. The NIH program focuses on a subset of small molecules, including new agents that improve the activity of established chemotherapeutics.
The patented therapy, which has been licensed to Tracon, has been studied in combination with the approved chemotherapeutic Temozolomide. Methoxyamine prevents cancer cells from repairing DNA damage caused by chemotherapy.
“The promise of overcoming a major mechanism of drug resistance in cancer is terrific news for many patients. We see potential applications in patients with brain cancers, melanoma, lung cancer and leukemia’s and perhaps other cancers,” said Stanton Gerson, director of the National Cancer Institute-designated Case Comprehensive Cancer Center.